Thoracic endovascular aortic repair or best medical therapy for uncomplicated type b aortic dissection? a meta-analysis.
To conduct a meta--analysis of all studies comparing thoracic endovascular aortic repair (TEVAR) and best medical therapy (BMT) for treating uncomplicated Type B aortic dissection (TBAD). PubMed/Medline and Web of Knowledge were searched till September 2014 for relevant studies published in English. Pooled odds ratio (OR) and its corresponding 95% CI were analyzed with Cochrane Review Manager (Revman 5.3). Our analysis showed that compared with BMT, TEVAR did not significantly affect 30--day (hospital) mortality. A significantly lower 1--year and 2-- or 3 year survival rates was observed with TEVAR vs BMT. Interestingly, a trend just short of statistical significance towards higher 4-- or 5--year survival was found with TEVAR treatment ( P = 0.08). No significant differences were found in false lumen (FL) thrombosis formation with TEVAR vs BMT treatment. However, a trend toward less incomplete or no FL thrombosis was noted with TEVAR. No significantly impact on the risk of later re--intervention was found with TEVAR vs BMT. TEVAR did not provide obvious early survival advantage for uncomplicated TBAD over BMT, especially in the patients using TEVAR alone. It may remain a treatment option in uncomplicated TBAD patients with high risks for later complications. More randomized, prospective, long--term studies are needed to further clarify whether TEVAR could be a better first--line treatment strategy vs BMT for uncomplicated TBAD.